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1. Introduction 
The high concentrations of oestriol-16a-glucuronide 
(E316G) present in maternal plasma, during late 
pregnancy, are largely of foeto-placental origin [1] 
and therefore a direct radioimmunoassay forthis 
steroid should be useful in assessing foetal well-being. 
Previous attempts [2-4] to raise specific antisera for 
E316G, using an antigen in which the steroid was 
linked to an immunogenic carrier via its native car- 
boxyl group, gave extremely variable cross-reactions 
(from < 1% to 53%) for oestriol (E3). However, even 
the most specific of these antisera ppeared to give 
an overestimation f 24% when incorporated into an 
assay [4]. Using a similarly linked antigen we have 
obtained antisera which, by traditional criteria [5], 
are highly specific; the cross-reaction for unconju- 
gated E3 being only 0.03%. Nevertheless, it was 
found that, under assay conditions, the presence of 
unconjugated E3 led to an overestimation f E316G. 
This apparently contradictory behaviour can be 
explained by the presence, in the antisera, of two 
distinct ypes of antibodies; binding to one of these 
types of antibody being dependent upon the presence 
of both the steroid and the glucuronic acid moieties, 
whereas for the other type of antibody the presence 
of the steroid alone is sufficient. The presence of 
these two types of antibodies, in varying ratios, would 
explain the findings of other workers [2-4].  
In our antisera the more specific (for E316G) type 
of antibody was predominant and the effect of the 
non-specific antibodies could be suppressed by 
presaturation with E3. This permitted the accurate 
measurement of E316G over a range of 0-200 pg in 
the presence of unconjugated E3. 
2. Materials and methods 
2.1. Reagents 
Steroid glucuronides, other than E316G were 
obtained from the MRC Reference Collection and 
unconjugated steroids were purchased from Steraloids 
Inc. Wilton, USA. Tritiated E3-16G (sp. act. 30 Ci/ 
mmole) and tritiated E3 (sp. act. 70 Ci/mmole) were 
obtained from the Radiochemical Centre, Amersham, 
UK. Scintillant (NE 260) was obtained from Nuclear 
Enterprises, Edinburgh and all samples were counted 
in 4 ml of this material. E316G was extracted from 
pregnancy urine and purified as the sodium salt [6]. 
General reagents were purchased from BDH and all 
solvents were redistilled prior to use. Freund's 
complete adjuvant was obtained from Difco 
Laboratories. 
2.2. Experimental 
The sodium salt of E316G was coupled to bovine 
serum albumin as previously described [7] and the 
resulting antigen injected into four adult, male New 
Zealand White rabbits using a previously described 
regimen [8]. Blood samples were removed ten days 
after the second booster injection and tested in the 
normal manner [9] using tritiated E316G as tracer. In 
addition one antiserum (R4B1) was also equilibrated 
with tritiated E3 and the ability of cold E 3 and cold 
E316G to displace this tracer measured. 
In order more nearly to simulate assay conditions, 
the displacing ability of E 316G in the presence of E3 
(in a 1:2 ratio; w/w) was compared with that of Ea 16G 
alone. This experiment was then repeated using anti- 
serum that had been presatumted with E3 (10 ng/ml 
of diluted antiserum). 
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3. Results 
The molar steroid:protein ratio of the conjugate 
was determined spectrally to be 12:1. The character- 
istics of the antisera, obtained using this antigen, were 
tested using a tritiated E316G tracer and the results 
are presented in table 1. Fig.1 shows the detailed 
displacement curves for Ea and E316G. The two 
responses are markedly non-parallel; E3 showing an 
initial phase in which it displaced tritiated E316G 
and then a second phase in which it caused virtually 
no further displacement, whereas E316G showed 
-i- 
tv~ 
O 
Z 
Z 
l :  3 - , / - - ,  
continuing displacement down to low levels of 
binding. 
When antiserum R4B1 was equilibrated at a dilu- 
tion of  500:1 with a tritiated Ea tracer, the displacing 
ability of cold Ea relative to that of Ea 16G was found 
to be 495%. 
Table 2 shows the displacing ability of E316G in 
the presence of  unconjugated Ea. The binding was 
read off from a standard curve, using Ea 16G alone. 
It can be seen that, using untreated antiserum, the 
presence of E3 consistently caused an overestimation 
of E316G. However, using antiserum presaturated 
with E3, this problem was overcome. 
The sensitivity of the standard curve, obtained 
using the pretreated antiserum (100/A), was found 
Table 2 
Measurement of Ea 16G in the presence of E3, using 
antiserum both with and without pretreatment 
E316G E 3 
(Pg) (Pg) 
E 316G Measured (pg) 
Untreated 
antiserum 
Treated 
antiserum 
0 0 0 0 
0~ , , , ' ~s  . . . .  ~ "¢: 2o 50 100 72 48 
COLD STEROID, ng 100 200 164 100 
150 300 192 150 
Fig.1. Displacement of tritiated E316G from antiserum R4B1 200 400 283 192 
with unlabelled E316G and E 3 . 
Table 1 
Cross-reactions (as %) of oestriol-16a-glucuronide antisera nd their working dilutions 
Steroid Antiserum 
R1 R2 R3 R4 
B1 B1 B1 B1 
Oestrone 5.0 <0.01 
Oestradiol 1.5 0.02 
Oestriol 58 5.0 100 0.03 
Oestriol-16~-glucuronide 100 100 100 100 
Oestrone-3-glucuronide <0.01 <0.01 
Oestradiol-3-glucuronide 0.04 <0.01 
Oestriol-3-glucuronide <0.01 <0.01 
Oestradiol-17~3-glucuronide 2.7 0.05 
Working Dilution 100:1 500:1 100:1 2000:1 
Coding of antisera: R1-R4 refers to 4 individual rabbits and B1 refers to blood samples 
removed after the 3rd injection. 
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to be 10 pg (least quantity of E316G distinguishable 
from the zero point withp < 0.001). 
4. Discussion 
It is possible to prepare steroid-specific antisera 
using antigens in which the steroid is linked through 
an existing functional group, providing that the 
accessible part of the steroid is unique [10]. In this 
context, it was felt that conjugation of E316G via 
the carboxyl group to an immunogenic carrier should 
allow recognition of the entire steroid and the majority 
of the glucuronide moiety. This line of thought was 
supported by the results presented in table 1, although 
there was considerable interanimal variation which is 
consistent with the variable results of other workers 
[2-4] .  
Although, by traditio~aal criteria [5], antiserum 
R4B1 was highly specific, a more detailed examination 
revealed that the displacement curve for E3 was 
biphasic; a likely explanation of this being the presence 
of two distinct ypes of antibody; one type binding 
both E 3 and E316G, whereas the other binds E316G 
exclusively. Both sets of antibodies would be initially 
loaded with tritiated E316G; the first phase ol ~ the E3 
displacement curve reflecting the ability of E3 to 
displace tritiated E316G from the less specific anti- 
bodies whereas in the second phase E3 is unable to 
cause displacement from the specific antibodies. 
The presence of two distinct ypes of antibody was 
clearly demonstrated by the following two experiments. 
First, the antiserum was loaded with tritiated E316G 
and the cross-reaction f E3 assessed in the normal 
manner [5] to be 0.03%. The antiserum was then 
loaded with tritiated E3 and, under these conditions, 
the cross-reaction for E~ was 495%. When tritiated 
E316G is used as the tracer, E3 gives a very low cross- 
reaction because much of this tracer is bound to the 
highly specific antibodies from which E3 cannot 
cause displacement. However, when tritiated E3 is 
used as tracer, it can only be bound by the less specific 
antibodies o that, under these conditions, the E3 
cross-reaction is very much higher. As this cross-reac- 
tion is much greater than 100%, these antibodies must 
show a preference for unconjugated E3. 
When antiserum R4BI was used to measure E316G 
in the presence of E3 there was a considerable over- 
estimation of E316G which can be attributed to 
displacement of tritiated E316G from the less specific 
antibodies by E3. This was remedied by presaturation 
of the antiserum with E3 which prevented any initial 
loading of the less specific antibodies with tritiated 
Eal6G; under these conditions the tracer would 
only bind to the specific antibodies and displacement 
could then only be effected by cold E 316G. It has 
been shown that the treated antiserum could com- 
pletely discriminate against E3 in a 2:1 ratio with 
E316G; this ratio being four times as great as that 
found in pregnancy plasma [1-1,12]. Late pregnancy 
plasma contains around 50 ng/ml of E316G [11] and 
so the sensitivity of the standard curve (10 pg) 
should be adequate. 
In conclusion, we have prepared an antiserum 
which should be adequate for the clinical measure- 
ment of E316G in pregnancy plasma. We have also 
illustrated that the commonly used 50% displacement 
method for testing antiserum specificity [5] can be 
extremely misleading in cases of pronounced non- 
parallelism. The problem being that, although large 
amounts of steroid may be required for 50% displace- 
ment, a small amount of the same steroid may 
produce a disproportionately large displacement. 
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